Neurogenic Orthostatic Hypotension
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
CuraSen TherapeuticsCST-3056
Theravance BiopharmaTD-9855
Clinical Trials (2)
Total enrollment: 46 patients across 2 trials
A Study in Subjects With Neurogenic Orthostatic Hypotension
Start: Sep 2025Est. completion: Mar 202612 patients
Phase 2Recruiting
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
Start: Sep 2017Est. completion: Nov 201834 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 46 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.